The novel endocrine disruptor tolylfluanid impairs insulin signaling in primary rodent and human adipocytes through a reduction in insulin receptor substrate-1 levels.
Robert M Sargis, Brian A Neel, Clifton O Brock, Yuxi Lin, Allison T Hickey, Daniel A Carlton, Matthew J Brady